Abstract Details

Title Alzheimer’s Disease Genetic Risk Variants Predict Cognitive Decline in Parkinson’s Disease

Topic Movement Disorders

Presentation(s) P2 - Poster Session 2 (5:30 PM-6:30 PM)

Poster/Presentation
Number 10-026

Objective To investigate whether susceptibility loci for Alzheimer's disease (AD) are associated with rates of longitudinal cognitive decline in Parkinson’s disease (PD).

Background

Parkinson’s disease is the second most prevalent neurodegenerative disease. In addition to the cardinal motor symptoms, the majority of PD patients experience significant cognitive impairment long-term. Cognitive impairment can arise and progress at any point in the disease course, while also varying widely in severity between individuals. At autopsy, the presence of co-morbid AD pathology – beta-amyloid plaques and tau neurofibrillary tangles – correlates with more severe cognitive outcomes, such as dementia, in PD. However, the role of common genetic variants that increase risk for AD in the development of cognitive decline and dementia in PD is poorly understood.

Design/Methods 151 clinically diagnosed PD patients were followed for 1-9.03 years (mean follow-up duration 2.9 years). PD patients with a baseline diagnosis of dementia were excluded. A linear mixed effects model was used to test for associations between long-term cognitive test performance (total Montreal Cognitive Assessment (MoCA) score) in PD and genotype at AD risk single nucleotide polymorphisms (SNPs) previously identified by genomewide association studies conducted in AD. Models adjusted for APOE genotype, sex, age, and baseline total MoCA score.

Results

SNPs at the CR1 (rs6656401), BIN1 (rs6733839), CLU (rs9331896), and PICALM (rs10792832) loci, previously associated with risk for developing AD, also independently predicted rates of longitudinal cognitive decline in PD.

Conclusions

Multiple genetic risk loci for AD predict longitudinal cognitive decline in non-demented PD patients. Future studies replicating these findings in additional longitudinally-followed PD cohorts are warranted.

Authors/Disclosures
Laura Baratta PRESENTER	No disclosure on file
Thomas F. Tropea, DO (University of Pennsylvania)	Dr. Tropea has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bial. The institution of Dr. Tropea has received research support from NINDS. The institution of Dr. Tropea has received research support from Parkinson Foundation. The institution of Dr. Tropea has received research support from Michael J Fox Foundation.
Krisna S. Maddy (University of Miami Miller School of Medicine - - Miami, FL)	Ms. Maddy has nothing to disclose.
Michael Guo, MD, PhD (University of Pennsylvania)	Dr. Guo has nothing to disclose.
Jacqueline Rick	No disclosure on file
John Q. Trojanowski, MD, PhD (University of PA School of Med)	Dr. Trojanowski has nothing to disclose.
Daniel Weintraub	Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Clintrex. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scion. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunovion. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Modality.ai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CuraSen. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorder Society. The institution of Daniel Weintraub has received research support from NIH. The institution of Daniel Weintraub has received research support from Fox Foundation. The institution of Daniel Weintraub has received research support from IPMDS. Daniel Weintraub has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
Alice Chen-Plotkin, MD	Dr. Chen-Plotkin has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��